(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Firstly, let us look at Eli Lilly’s stock performance. LLY stock has seen extremely strong gains of 345% from levels of $170 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly lifts 2024 sales view by $2 billion on weight-loss drug demand Updated / Tuesday, 30 Apr ... The drugmaker also raised its annual profit forecast by $1.30 per share to $13.50 to $14 per ...
Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average ...
But other companies aim to get in on the billion-dollar market, and just recently, big biotech Amgen ( AMGN -0.71%) reported ...
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...